Anticancer agents are used to control local tumors and/ or to prevent systemic metastasis. For the former purpose, an ideal method is to administer the drugs to tumors topically. Currently, most anticancer agents are given systemically, and their adverse effects are unavoidable. Regional infusion is a method of locally applying anticancer agents, but even with this method, systemic effects are not negligible. Another method of treating tumors efficiently by decreasing damage to normal tissues is the use of prodrugs. Most of the previously developed prodrugs are activated in vivo through enzymatic processes. [1] [2] [3] [4] If the appropriate enzymes are more abundant in tumor tissue or can be delivered to a tumor using monoclonal antibodies, selective treatment of tumors becomes possible. Recently, a new method of activating prodrugs, i.e., enzyme prodrug gene therapy, is attracting more attention. [5] [6] [7] Another novel class of tumor-specific prodrugs which we describe here is activated by hypoxic irradiation. In their previous study, Nishimoto et al. 8) found that an N(1)-C(5)-linked dimer of 5-fluorouracil (5-FU) was converted to 5-FU following irradiation. This conversion occurred more efficiently when the dimer was irradiated under hypoxic conditions than when it was irradiated under aerobic conditions. Radiation is intended to be applied to tumor sites only, and in addition, hypoxic cells are thought to be present only in tumors. Therefore, this type of prodrug appeared promising in terms of selective tumor treatment. The conversion of the 5-FU dimer into 5-FU was not so efficient and not so specific to hypoxic conditions, 8) so no further investigation of this compound was performed. Instead, we searched for various other compounds that release 5-FU in response to hypoxic irradiation through a similar mechanism.
Recently, we have found that a series of compounds with 2-oxoalkyl side chains at the N(1)-position of 5-FU are converted efficiently to 5-FU following hypoxic irradiation. 9) Among approximately 30 compounds synthesized and tested, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) is a prototype compound in terms of the simplest side-chain
To whom all correspondence should be addressed. E-mail: yuta@frontier.kyoto-u.ac.jp structure. The proposed mechanism of 5-FU release by irradiation is shown in Fig. 1 . Hydrated electrons (e − aq ) are thought to be incorporated into the compound to form the corresponding π * anion radical, which is thermally activated to the σ * anion radical with a weakened C(1′)-N(1) bond. Subsequently, hydrolytic dissociation of the C(1′)-N(1) bond occurs, releasing 5-FU. In this study, we investigated the radiation chemical reactivity and the in vitro antitumor effect of OFU001.
MATERIALS AND METHODS

Compound
This compound has been reported by a Korean group 10) as one of a series of acyclic 5-substituted pyrimidine nucleoside analogues. For this study, we synthesized OFU001 by reaction of 2,4-bis(trimethylsilyloxy)-5-fluoropyrimidine (1.21 g) and bromoacetone (5.0 ml) in acetonitrile under an N 2 atmosphere. After 1 h of refluxing, 1.0 ml of methanol was added to the reaction mixture, and the mixture was stirred for 30 min at room temperature. The product was separated and purified by silica gel column chromatography (yield 53%) and identified by nuclear magnetic resonance and high-resolution mass spectroscopy. OFU001 has a molecular weight of 186. The partition coefficient in octanol/water measured by a published method 11) was 0.067. As a reference compound, 5-FU obtained from Tokyo Kasei Organic Chemicals (Tokyo) was also used. Radiation chemistry To measure radiolytic decomposition of OFU001 and release of 5-FU, OFU001 dissolved in phosphate buffer (pH 7.0) was irradiated with an X-ray apparatus (250 kVp, 15 mA, 1.0 mm Al filter) at a dose rate of 5 Gy/min under aerobic or hypoxic conditions at room temperature. To establish hypoxia, Ar gas was bubbled for 15 min according to a published method 12) and the test tubes were then sealed. Immediately thereafter, the solution was subjected to high-performance liquid chromatography (HPLC) analysis. HPLC was performed using a NANOSPACE SI-1 (Shiseido, Tokyo) equipped with a UG120 C18 semimicro-column (1.5 mmφ×250 mm), and the elution peaks were detected using a UV-VIS detector 2002 at 264 nm wavelength. Phosphate buffer containing 1% methanol (pH 3) was used as an eluent. In vitro effects Exponentially growing murine SCCVII cells with a doubling time of 14 h were used. The cells were cultured in Eagle's minimum essential medium (MEM) containing 12.5% fetal bovine serum. In all experiments, colonies containing 50 or more cells were counted after fixation on day 7 following drug treatment. The control plating efficiency of this cell line was 63±7 (SD) % during the experiments. To investigate the cytotoxicity of irradiated and unirradiated OFU001, 250 SCCVII cells were plated onto each culture dish 7.5 h before treatment with the drugs. MEM containing 1 mM OFU001 was irradiated with 7.5-30 Gy under aerobic or hypoxic conditions. To make the drug-containing medium hypoxic, it was bubbled with 95% N 2 /5% CO 2 gas for 15 min and then the flask was sealed. After irradiation with 4 MV X rays at a dose rate of 5 Gy/min, the drug-containing MEM was supplemented with fetal bovine serum at 10%, and then the medium in the dishes containing SCCVII cells was replaced with drug-containing medium. After 1, 3, 6, 12, or 24 h, the drug-containing medium was discarded, and the cultures were washed once with phosphate-buffered saline, and supplemented with fresh medium. For controls, MEM containing no drug was also bubbled with the gas, irradiated, and added to control cell cultures; bubbling and irradiation of MEM did not change the plating efficiency of SCCVII cells. Also, one group of cell cultures was treated with unirradiated OFU001 after bubbling with the gas.
The cytotoxicity of 5-FU was also investigated using SCCVII cells. As in the experiment with OFU001, exponentially growing 250 SCCVII cells were plated onto dishes. After 7.5 h, the medium was replaced with MEM containing 2.5, 5, or 10 µM 5-FU and 10% serum, and 1, 3, 6, 12, or 24 h later, the drug-containing medium was removed, then the cultures were washed once, and replenished with fresh MEM.
Since OFU001 possesses electron-capturing capacity, the electron-affinic radiosensitizing activity of OFU001 was also investigated. Following published methods, 13) SCCVII cells were treated with 1 mM OFU001 in sealed test tubes 40 min prior to and during irradiation under hypoxic conditions. The concentration of 1 mM has been most often used to test radiosensitizers in our laboratory. 11, 13) Immediately after irradiation with 4 MV X rays, the drug was removed by centrifugation and the cells were replated. To investigate aerobic radiosensitization, SCCVII cells plated 7.5 h beforehand were treated in dishes with 1 mM OFU001 40 min prior to and during irradiation. After irradiation, the drug-containing medium was removed, and the cultures were washed, and replenished with fresh medium. Fig. 2 shows dose-response curves for the decomposition of OFU001 and the release of 5-FU upon irradiation of a solution of 0.1 mM OFU001 in phosphate buffer under aerobic or hypoxic conditions. Both reactions were radiation-dose dependent, and the doseresponse curves could be fitted with straight lines by linear regression (all r>0.988, P<0.05). While the decomposition of OFU001 was slightly more efficient with hypoxic radiolysis than with aerobic radiolysis, the release of 5-FU was greatly enhanced under hypoxic conditions. The Gvalue (mol number of molecules that are decomposed or produced by 1 J of absorbed radiation energy) for decomposition of OFU001 was 3.4 (95% confidence interval, CI, 3.1 to 3.8)×10
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−7 mol/J under hypoxic conditions and 2.5
(CI, 2.1 to 2.9)×10 −7 mol/J under aerobic conditions, while the G-values for release of 5-FU were 1.9 (CI, 1.8 to 2.0)×10 −7 mol/J and 1.0 (CI, 0.95 to 1.04)×10 −8 mol/J, respectively. Thus, 55% of decomposed OFU001 was converted to 5-FU upon irradiation under hypoxic conditions. The release of 5-FU from OFU001 (0.1 mM) in MEM occurred with the same efficiency as in the phosphate buffer, with a G-value for 5-FU release of 1.9 (CI, 1.7 to 2.2)×10 −7 mol/J. The release of 5-FU was substantially identical (G-value: 1.9 [CI, 1.8 to 2.0]×10 − 7 mol/J) even when the concentration of OFU001 was increased to 1 mM.
The metabolites of OFU001 other than 5-FU produced by aerobic and hypoxic irradiation are now under investigation. Following aerobic irradiation, there were three major peaks on the HPLC chart. One of them has been shown to represent 1-(2′-oxopropyl)-5-hydroxyuracil, and the identity of the other two major metabolites is now being determined (data to be published). Following hypoxic irradiation, however, there were no major peaks other than those for OFU001 and 5-FU on the HPLC chart. In vitro effects Fig. 3 compares the cytotoxic effects of irradiated and unirradiated OFU001. OFU001 aerobically irradiated with 30 Gy or unirradiated OFU001 showed minimal cytotoxicity, and after 24 h of contact with them, only 15-19% of SCCVII cells were killed. On the other hand, OFU001 hypoxically irradiated with 30 Gy showed much higher cytotoxicity; the cell survival was 29% (95% CI, 24 to 39%) after 24 h of contact. This cytotoxic effect was clearly dependent on the drug contact time and the radiation dose. Fig. 4 shows the cytotoxic effect of 5-FU on SCCVII cells. The effect was dependent on the concentration and contact time. The effects of 5-FU at 2.5 and 5 µM were nearly equivalent to those of OFU001 irradiated hypoxically with 15 and 30 Gy, respectively. From Fig. 2 , the concentration of 5-FU released from OFU001 is estimated to be 2.8 µM at 15 Gy of hypoxic irradiation and 5.5 µM at 30 Gy. Since 10% serum was added to the medium containing OFU001 after irradiation, the final concentration of 5-FU in the medium should be approximately 2.5 µM after 15 Gy and 5 µM after 30 Gy. Thus, the cytotoxic effects of hypoxically irradiated OFU001 agreed well with those of 5-FU at the corresponding concentrations. Fig. 5 shows the absence of a radiosensitizing effect of OFU001. When OFU001 was removed immediately after irradiation, the compound (1 mM) had no effect under either aerobic or hypoxic conditions.
DISCUSSION
Among various types of antitumor prodrugs, OFU001, which is activated by hypoxic irradiation, clearly represents a novel class. Regarding the mechanism of activation shown in Fig. 1 , attempts are being made in our laboratory to confirm the formation of the anion radical intermediates using pulse radiolysis. In this regard, Mori et al. 14) have detected the transient absorption of carbonyl π * anion radicals following hypoxic irradiation of the N(1)-C(5) linked 5-FU dimer in solution in phosphate buffer. The incorporation of the radiochemically generated hydrated electron into the carbonyl group of electron-affinic compounds was previously reported by Adams and Dewey.
15) The contribution of the σ * anion radical that is in resonance with the π * anion radical to the reductive dissociation of the C-Cl bond has been discussed by Santiago et al. 16 ) Therefore, the reaction process shown in Fig. 1 is a combination of two reactions that were previously reported independently. Hydrated electrons are abundantly produced during hypoxic irradiation, but upon aerobic irradiation, the hydrated electrons are captured by electron-affinic oxygen to form reactive superoxide anion radicals (O ). Therefore, this type of activation of OFU001 is essentially specific to irradiation under hypoxic conditions. The 2-oxo structure of the side chains at the N(1)-position of 5-FU • has been proven to play a crucial role in the release of 5-FU. 9) In contrast to OFU001, an analogue of OFU001 bearing a 1-propyl substituent without the 2-oxo function released no 5-FU upon irradiation under hypoxic conditions. 9) Recently, Wilson et al. 17) reported prodrugs of mechlorethamine which are activated by metabolic or radiolytic nitroreduction under hypoxic conditions. Those compounds are also hypoxia-specific, but their mechanism of activation is different from that of our compound.
Among many prodrugs that we have investigated, OFU001 possesses the simplest side chain and has one of the highest efficiencies of releasing 5-FU. The G-value of 1.9×10 −7 mol/J for 5-FU release was much higher than that of the previously reported 5-FU dimer (7.5×10 −8 mol/ J).
8) Therefore, we investigated the efficacy of OFU001 in more detail. It exhibited good characteristics as a prodrug in in vitro experiments. OFU001 itself had very low cytotoxicity against SCCVII cells. In phosphate buffer, OFU001 was converted 19 times more efficiently into 5-FU following hypoxic than aerobic irradiation. This Gvalue ratio (hypoxia to air) was much higher than that (2.4) for the 5-FU dimer. 8) In accord with the radiation chemical reactivity, OFU001 had very low cytotoxicity when irradiated aerobically, but it showed definite effects when irradiated hypoxically. The cytotoxic effects of a given concentration of hypoxically irradiated OFU001 against SCCVII cells were similar to those of 5-FU at a concentration equivalent to that released by the OFU001. This observation suggests that the other byproducts derived from radiolysis of OFU001 are not cytotoxic.
This process of radiation activation is expected to work also in vivo, and we have started in vivo evaluation of this compound. In a preliminary study, we have observed release of 5-FU in in vivo tumors following intraperitoneal injection of OFU001 and irradiation of air-breathing mice. The amount of 5-FU release was similar to that expected from the in vitro experiments (Shibamoto et al., data to be published). When 5 µM 5-FU is released within hypoxic tumor cells, some degree of in vivo effect may be expected, judging from the clinically achievable 5-FU concentrations in tumors and the effect of 5-FU at those dosages. 18, 19) To obtain this concentration of 5-FU, however, radiation doses of 25-30 Gy are necessary. These doses are used in clinics for intraoperative radiotherapy and radiosurgery, which are rapidly being introduced worldwide. So, OFU001 may be useful in clinics when combined with these treatment modalities, but more efficient compounds would be more suitable for clinical application.
We have therefore surveyed many other compounds having various 2-oxo side chains at the N(1)-position of 5-FU. Some compounds showed slightly, but not greatly, higher efficiency of release of 5-FU than OFU001, and at present it seems difficult to develop prodrugs of 5-FU which are more suitable for clinical application using this idea. However, we have confirmed that the concept of hypoxic radiation activation is applicable to other antitumor and cytotoxic agents (Nishimoto et al., unpublished data) . The 2-oxo side-chain structure seems to be important for developing radiation-activated prodrugs of other anticancer agents, as well. We have already synthesized several prodrugs of 5-fluoro-2′-deoxyuridine (FdUrd) having this type of side chain at their N(3)-position and are now investigating these compounds. FdUrd is one order of magnitude more efficient than 5-FU, in terms of the IC 50 (molar concentration causing 50% growth inhibition) values in most cell lines. 20) Thus, FdUrd-releasing prodrugs are expected to work better than 5-FU-releasing prodrugs, including OFU001. Furthermore, we are investigating various other anticancer drugs, such as mitomycin C, that are more efficient on a molar concentration basis than 5-FU and FdUrd and are capable of carrying 2-oxoalkyl side chains.
